Talkspace Becomes First Behavioral Health Provider to Integrate with Amazon Pharmacy, Offering Psychiatry Services and a More Seamless Medication Management Experience
Mental health medication adherence remains a significant challenge in the U.S., with adherence rates ranging between 45% and 55% for many common conditions. Cost and access are two of the most persistent barriers. A study published in JAMA Psychiatry found that 21% of individuals with depression did not fill a prescribed medication in the past year due to cost concerns.
Now, Talkspace members can more seamlessly fulfill prescriptions from their Talkspace provider through Amazon Pharmacy.
'This partnership builds on our successful collaboration with Amazon's Health Benefits Connector last year and represents another way consumers can access the care they need,' said Jon Cohen, MD, CEO of Talkspace. 'Psychiatric medication is most effective when paired with therapy, and this integration with Amazon Pharmacy allows us to deliver truly comprehensive care—from diagnosis to ongoing treatment—all in one streamlined experience.'
Here's how it works: New and returning Talkspace customers nationwide can easily select Amazon Pharmacy as a fast, free home delivery option. If the patient chooses, their Talkspace psychiatric provider can send prescriptions directly to Amazon Pharmacy with a single click.
Amazon Pharmacy offers convenient, fast home delivery, sends refill reminders to patients, and helps improve medication adherence. Many commonly prescribed medications are available through RxPass, Amazon Pharmacy's $5-a-month subscription savings program.
Customers shopping on Amazon can also check to see if they have coverage for Talkspace therapy and psychiatry services through Amazon's Health Benefits Connector website. Eligible customers can seamlessly enroll and schedule a virtual appointment with a licensed provider, typically within 1-5 days.
'We're committed to making it easier for people to get the medications they need—at a price they can afford and when they need them,' said Tanvi Patel, Vice President and General Manager of Amazon Pharmacy. 'Talkspace is an established leader in mental health care, and we're pleased to work together to provide a seamless, digital-first experience that helps customers more easily manage both their care and prescriptions from start to finish.'
About Talkspace
Talkspace (NASDAQ: TALK) is a leading virtual behavioral healthcare provider committed to helping people lead healthier, happier lives through access to high-quality mental healthcare. At Talkspace, we believe that mental healthcare is core to overall health and should be available to everyone.
Talkspace pioneered the ability to text with a licensed therapist from anywhere and now offers a comprehensive suite of mental health services, including therapy for individuals, teens, and couples, as well as psychiatric treatment and medication management (18+). With Talkspace's core therapy offerings, members are matched with one of thousands of licensed therapists within days and can engage in live video, audio, or chat sessions, and/or unlimited asynchronous text messaging sessions.
All care offered at Talkspace is delivered through an easy-to-use, fully-encrypted web and mobile platform that meets HIPAA, federal, and state regulatory requirements. Most Americans have access to Talkspace through their health insurance plans, employee assistance programs, our partnerships with leading healthcare companies, or as a free benefit through their employer, school, or government agency.
For more information, visit www.talkspace.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
31 minutes ago
- Business Wire
Modivcare Regains Compliance with Nasdaq Continued Listing Standard
DENVER--(BUSINESS WIRE)--Modivcare Inc. (the 'Company' or 'Modivcare') (Nasdaq: MODV), a technology-enabled healthcare services company that provides a platform of integrated supportive care solutions focused on improving health outcomes, today announced it has regained compliance with Rule 5450(b)(3)(C) of the Nasdaq Stock Market LLC ('Nasdaq') regarding the Company's market value of publicly held shares ('MVPHS'). On July 7, 2025, the Company received confirmation from Nasdaq that it regained compliance with the MVPHS requirement for continued listing on Nasdaq, having confirmed that the Company's MVPHS had been above $15 million for at least the last 20 consecutive business days. Accordingly, the Company again satisfies all Nasdaq listing standards required for continued listing on The Nasdaq Global Select Market. 'We are pleased to regain full compliance with Nasdaq listing standards, and to have achieved this by means of stock performance and appreciation,' said L. Heath Sampson, President and CEO. 'We are continuing our efforts to enhance enterprise value and build a stronger, more connected Modivcare.' ModivCare will continue to be traded on The Nasdaq Global Select Market, subject to its continued compliance with all applicable listing requirements. About Modivcare Modivcare Inc. ("Modivcare") is a technology-enabled healthcare services company that provides a suite of integrated supportive care solutions for public and private payors and their members. Modivcare's value-based solutions address the social determinants of health (SDoH) by connecting members to essential care services. By doing so, Modivcare helps health plans manage risks, reduce costs, and improve health outcomes. Modivcare serves as a provider of non-emergency medical transportation (NEMT), personal care services (PCS), and in-home monitoring solutions (Monitoring). To learn more about Modivcare, please visit Forward-Looking Statements Certain statements contained in this press release constitute 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are predictive in nature and are frequently identified by the use of terms such as 'may,' 'will,' 'should,' 'expect,' 'believe,' 'estimate,' 'intend,' and similar words indicating possible future expectations, events or actions. Such forward-looking statements are based on current expectations, assumptions, estimates and projections about our business and our industry, and are not guarantees of our future performance. These statements are subject to a number of known and unknown risks, uncertainties and other factors, many of which are beyond our ability to control or predict, which may cause actual results to be materially different from those expressed or implied herein. The Company has provided additional information about the risks facing its business in its most recent annual report on Form 10-K and any subsequent periodic and current reports on Forms 10-Q and 8-K filed by it with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statement was made and are expressly qualified in their entirety by the cautionary statements set forth herein and in our filings with the Securities and Exchange Commission, which you should read in their entirety before making an investment decision with respect to our securities. We undertake no obligation to update or revise any forward-looking statements contained in this release, whether as a result of new information, future events or otherwise, except as required by applicable law.
Business Wire
34 minutes ago
- Business Wire
European Commission Approves TEVIMBRA ® in Combination with Chemotherapy as a First-Line Treatment for Nasopharyngeal Carcinoma
SAN CARLOS, Calif.--(BUSINESS WIRE)-- BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Commission has approved TEVIMBRA ® (tislelizumab), in combination with gemcitabine and cisplatin, for the first-line treatment of adult patients with metastatic or recurrent nasopharyngeal carcinoma (NPC), not amenable to curative surgery or radiotherapy. Nasopharyngeal carcinoma is a rare cancer in which malignant cells form in the nasopharynx, the upper part of the throat located behind the nose. 1 'The approval of TEVIMBRA combined with chemotherapy in Europe marks an important advancement for people with recurrent or metastatic nasopharyngeal carcinoma—a rare and challenging disease,' said Prof. Lisa Licitra, Chief of the Head and Neck Cancer Medical Oncology Department at Fondazione IRCCS Istituto Nazionale dei Tumori in Milan, Italy. 'Thanks to the compelling results from the RATIONALE-309 study, we now have a powerful new treatment that not only delays disease progression but also helps patients live longer. This approval brings new hope and a clinically proven option to patients who urgently need better care.' The approval in NPC is based on results of RATIONALE-309 (NCT03924986), a double-blind, placebo-controlled, multicenter, Phase 3 study, which randomized 263 treatment-naïve patients who received either TEVIMBRA in combination with gemcitabine plus cisplatin or placebo in combination with gemcitabine plus cisplatin. The primary endpoint was met at the first prespecified interim analysis in which TEVIMBRA significantly prolonged progression-free survival (PFS) in the intent-to-treat (ITT) population (HR 0.52 [95% CI:0.38, 0.73] p<0.0001), showing a 48% reduction in the risk of disease progression or death. The median PFS in the TEVIMBRA plus chemotherapy arm was 9.2 months compared to 7.4 months in the placebo plus chemotherapy arm. An updated analysis with an additional 12 months of follow-up showed efficacy results consistent with the interim analysis. Clinically meaningful and sustained improvement in overall survival (OS) was observed, with a median OS of 45.3 months for TEVIMBRA plus chemotherapy compared to 31.8 months for placebo plus chemotherapy. TEVIMBRA plus chemotherapy was generally well tolerated, and no new safety signals were identified. Pooled safety data included over 3,900 patients who received TEVIMBRA, either as monotherapy (n=1,952) or in combination with chemotherapy (n=1,950), at the approved dosing regimen. The most common Grade 3 or 4 adverse reactions (≥ 10%) associated with TEVIMBRA given in combination with chemotherapy were neutropenia, anemia, and thrombocytopenia. 'Following our recent EU approval of TEVIMBRA for extensive-stage small cell lung cancer, this new authorization in nasopharyngeal carcinoma reflects strong momentum in broadening access to our immunotherapy across solid tumors,' said Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne. 'With a comprehensive EU label spanning lung and gastrointestinal cancers, and more than 100 regulatory approvals globally, we are delivering on our ambition to bring innovative therapies to more patients around the world.' TEVIMBRA was previously approved in the EU as a first-line treatment for eligible patients with gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, as a first-line treatment for unresectable esophageal squamous cell carcinoma (ESCC), as a second-line treatment in ESCC after prior platinum-based chemotherapy, as a first-line treatment for extensive-stage small cell lung cancer (ES-SCLC), and for three non-small cell lung cancer (NSCLC) indications covering both the first- and second-line settings. About Nasopharyngeal Cancer (NPC) Nasopharyngeal cancer, also known as nasopharyngeal carcinoma, is a type of head and neck cancer that starts in the nasopharynx, the upper throat passage that connects the nose to the lungs. 2 NPC, which can be categorized into different pathological subtypes (keratinizing squamous, non-keratinizing, and basaloid squamous) 3, is often diagnosed at advanced stages due to its deep anatomical location and mild early symptoms, making early detection challenging. 4 In 2020, NPC accounted for approximately 133,000 new cancer cases and 80,000 deaths per year globally and exhibits a unique geographical pattern, with its prevalence notably concentrated in Asia. 5 While the overall 5-year survival rate for NPC is approximately 63%, in advanced disease the survival rate decreases to 49%. 6 About TEVIMBRA (tislelizumab) TEVIMBRA is a uniquely designed humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcγ) receptors on macrophages, helping to aid the body's immune cells to detect and fight tumors. TEVIMBRA is the foundational asset of BeOne's solid tumor portfolio and has shown potential across multiple tumor types and disease settings. The global TEVIMBRA clinical development program includes almost 14,000 patients enrolled to date in 35 countries and regions across 70 trials, including 21 registration-enabling studies. TEVIMBRA is approved in 46 countries, and more than 1.5 million patients have been treated globally. Important Safety Information The current European Summary of Product Characteristics (SmPC) for TEVIMBRA is available from the European Medicines Agency. This information is intended for a global audience. Product availability and approved indications vary by country. Please refer to local prescribing information for complete details. About BeOne BeOne Medicines is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. With a growing global team of more than 11,000 colleagues spanning six continents, the Company is committed to radically improving access to medicines for far more patients who need them. To learn more about BeOne, please visit and follow us on LinkedIn, X, Facebook and Instagram. Forward-Looking Statement This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the ability of TEVIMBRA plus chemotherapy to significantly reduce the risk of disease progression or death for patients with recurrent or metastatic NPC; BeOne's ability to expand patient access to cancer treatments; and BeOne's plans, commitments, aspirations, and goals under the heading 'About BeOne.' Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeOne's ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing, and progress of clinical trials and marketing approval; BeOne's ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeOne's ability to obtain and maintain protection of intellectual property for its medicines and technology; BeOne's reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeOne's limited experience in obtaining regulatory approvals and commercializing pharmaceutical products and its ability to obtain additional funding for operations and to complete the development of its drug candidates and achieve and maintain profitability; and those risks more fully discussed in the section entitled 'Risk Factors' in BeOne's most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeOne's subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeOne undertakes no duty to update such information unless required by law. To access BeOne media resources, please visit our Newsroom. 1 National Cancer Institute at the National Institutes of Health. Nasopharyngeal Cancer Treatment (PDQ®)–Patient Version. 2 Cleveland Clinic. Nasopharynx. 3 American Cancer Society. What Is Nasopharyngeal Cancer? 4 Wei, X., et al. (2024) Nasopharyngeal cancer risk assessment by country or region worldwide from 1990 to 2019. BMC Public Health, 24, 1931. 5 Yang, Y., et al. (2023) Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309). Cancer Cell, 41(7): 1061–1072. 6 American Cancer Society. Survival Rates for Nasopharyngeal Cancer.
USA Today
2 hours ago
- USA Today
🚨 The Penetrex muscle cream with 35,000 5-star reviews is 30% off for Prime Day
Don't miss this limited-time Prime Day discount on a 3-pack of the best-selling muscle relief cream. If you're looking to stay active and pain-free this summer, Penetrex Joint & Muscle Therapy Cream is a must-have in your wellness toolkit. Whether you're a teacher, retail worker or someone who deals with chronic pain, this top-rated muscle cream offers fast, targeted relief and is on sale just in time for Amazon Prime Day 2025. With nearly 35,000 five-star Amazon reviews, Penetrex has become a go-to solution for people dealing with: The non-greasy, fast-absorbing formula makes this Penetrex cream great for daily use, especially during the hot summer months when you want relief without the mess. As part of Amazon's Prime Day 2025 sale this week, Penetrex is available at a limited-time discount, and is one of the hottest wellness deals of the season. Early Amazon Prime Day deal: Save on Penetrex Normally $124.95 for a 3-pack, you can save 30% and ring up at $87.21 today. Penetrex Daily Joint + Muscle Care Intensive Concentrate Cream Save on this insanely popular joint and muscle comfort cream during Amazon Prime Day 2025 this week. Buy now at Amazon What is Penetrex Daily Joint & Muscle Care Intensive Concentrate Cream? The Penetrex Daily Joint & Muscle Care Intensive Concentrate Cream is a topical muscle and joint relief cream with nearly 62,000 5-star reviews on Amazon. The topical solution is formulated with a combination of natural ingredients including Arnica, Vitamin B6, MSM, and Boswellia. The fast-acting cream has an effective transdermal delivery system that allows it to penetrate into the skin for long-lasting relief from inflammation. Penetrex has become a go-to product for nurses to alleviate discomfort during long shifts. Shop Penetrex on sale at Amazon What do customers like about Penetrex cream? When is Amazon Prime Day? The 2025 Prime Day sale starts on Tuesday, July 8 and will wind down on Friday, July 11. → More: Is an Amazon Prime membership worth it? Here's what you need to know
